Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Glioma 7Wilms Tumor 6Rhabdoid Tumor 5Osteosarcoma 5Neuroectodermal Tumors, Primitive, Peripheral 5Neuroblastoma 5Multiple Myeloma 5Medulloblastoma 5Lymphoma, Non-Hodgkin 5Leukemia, Myeloid, Acute 5Histiocytosis, Langerhans-Cell 5Hepatoblastoma 5Ependymoma 5Sarcoma 4Rhabdomyosarcoma 4Myelodysplastic Syndromes 4Lymphoma 4Lung Neoplasms 4Central Nervous System Neoplasms 4Breast Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Colorectal Neoplasms 3Burkitt Lymphoma 3Sarcoma, Ewing 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neuroendocrine Tumors 2Mycosis Fungoides 2Melanoma 2Malignant Solid Neoplasm 2

Interventions

cabozantinib 1X-Rays 1Specimen Handling 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non functioning pancreatic endocrine tumor × X-Rays × 30 days × Clear all
NCT03375320 2026-06-03

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡